A Phase II Trial of Myeloablative Conditioning and Transplantation of HLA-matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated (MUD) Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To estimate the overall survival (OS) at 1 year following HLA-matched, Partially HLA-mismatched, HLA-haploidentical or matched unrelated Bone Marrow for Patients with Refractory Severe Aplastic Anemia
1 year
Yes
Robert A Brodsky, MD
Principal Investigator
The Johns Hopkins University
United States: Institutional Review Board
J10117
NCT01383434
June 2011
June 2014
Name | Location |
---|---|
The Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland 21231 |